IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

Sandra P.  D'Angelo

Consulting or Advisory Role - Adaptimmune; Amgen; EMD Serono; GlaxoSmithKline; Immune design; Immunocore; Incyte; Merck; Nektar

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)

Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar

Jonathan Christopher  Noujaim

Consulting or Advisory Role - Bayer

Fiona  Thistlethwaite

Honoraria - Bayer

Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst); T-Knife; Zelluna

Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)

Travel, Accommodations, Expenses - GlaxoSmithKline; Zelluna

Other Relationship - iMatch

Albiruni Ryan  Abdul Razak

Consulting or Advisory Role - Adaptimmune; Bayer; Merck

Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Pfizer; Roche/Genentech

Silvia  Stacchiotti

Honoraria - GlaxoSmithKline; Lilly; Novartis; PharmaMar

Consulting or Advisory Role - Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Lilly; MaxiVax; Novartis; PharmaMar

Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines; Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)

Travel, Accommodations, Expenses - PharmaMar

Warren Allen  Chow

Consulting or Advisory Role - GlaxoSmithKline

Speakers' Bureau - Novartis

Research Funding - Novartis (Inst)

Travel, Accommodations, Expenses - GlaxoSmithKline

Other Relationship - Advenchen Laboratories; Via Oncology

John B. A. G.  Haanen

Stock and Other Ownership Interests  - Neogene Therapeutics

Consulting or Advisory Role - Achilles Therapeutics (Inst); AIMM Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Third Rock Ventures (Inst)

Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)

Anna Weinberg  Chalmers

Consulting or Advisory Role - DePuy Companies (I)

Research Funding - Blueprint Medicines; GlaxoSmithKline; TRACON Pharma

Patents, Royalties, Other Intellectual Property - patent pending for hormone supplementation of tendon and ligament repair (I)

Steven Ian  Robinson

Honoraria - BTG

Research Funding - TRACON Pharma (Inst)

Brian Andrew  Van Tine

Leadership - Polaris

Consulting or Advisory Role - Adaptimmune; Apexigen; Bayer; Cytokinetics; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Lilly; Novartis; Pfizer

Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis

Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma

Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeuticuses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker

Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly

Kristen N.  Ganjoo

Consulting or Advisory Role - Daiichi Sankyo; Deciphera; Foundation Medicine

Melissa L.  Johnson

Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Association of Community Cancer Centers (ACCC); AstraZeneca; Atreca; Boehringer Ingelheim; Calithera Biosciences; Genentech/Roche; GlaxoSmithKline; Gritstone Bio; Guardant Health; Incyte; Janssen; Lilly; Loxo; Merck; Mirati Therapeutics; Novartis; Pfizer; Ribon Therapeutics; Sanofi

Research Funding - Acerta Pharma; Adaptimmune; Amgen; Apexigen; Arcus Biosciences; Array BioPharma; BeiGene; Birdie; Checkpoint Therapeutics; Corvus Pharmaceuticals; CytomX Therapeutics; Daiichi Sankyo; Dynavax Technologies; EMD Serono; Genmab; Genocea Biosciences; Hengrui Pharmaceutical ; Immunocore; Janssen; Jounce Therapeutics; Kadmon; Lycera; Neovia Oncology; OncoMed; Regeneron; Shattuck Labs; Stem CentRX; Syndax; Takeda; Tarveda Therapeutics; TCR2 Therapeutics; WindMIL

Travel, Accommodations, Expenses - AbbVie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Sysmex; Vapotherm

Victoria L.  Chiou

Employment - AstraZeneca/MedImmune; GlaxoSmithKline

Stock and Other Ownership Interests  - AstraZeneca/MedImmune; GlaxoSmithKline

Research Funding - AstraZeneca/MedImmune; GlaxoSmithKline

Patents, Royalties, Other Intellectual Property - Inventor on patent pending for discovery relating to health and medicine (Inst)

Travel, Accommodations, Expenses - AstraZeneca/MedImmune

Thomas H.  Faitg

Employment - GlaxoSmithKline

Stock and Other Ownership Interests  - GlaxoSmithKline

Mary  Woessner

No Relationships to Disclose

Laura  Pearce

No Relationships to Disclose

Aiman  Shalabi

Employment - GlaxoSmithKline

Stock and Other Ownership Interests  - GlaxoSmithKline

Travel, Accommodations, Expenses - GlaxoSmithKline

Other Relationship - GlaxoSmithKline

Jean-Yves  Blay

Leadership - Innate Pharma

Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche

Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Pharmamar; Roche

Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Roche

George  Demetri

Leadership - Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Biotechnology; Erasca, Inc; G1 Therapeutics; Merrimack; Relay Therapeutics; Translate BIO

Stock and Other Ownership Interests  - Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Biotechnology; Erasca, Inc; G1 Therapeutics; Merrimack; Relay Therapeutics; Translate BIO

Consulting or Advisory Role - EMD Serono; GlaxoSmithKline; ICON Clinical Research; MEDSCAPE; OncLive/MJH Life Sciences; Polaris; Sanofi; WCG/Arsenal Capital Partners

Research Funding - AbbVie; Adaptimmune; Bayer; Daiichi Sankyo; Epizyme; GlaxoSmithKline; Ignyta; Janssen; Loxo; Mirati Therapeutics; Novartis; Pfizer; PharmaMar; Roche/Genentech; ZIOPHARM Oncology

Patents, Royalties, Other Intellectual Property - Novartis

Other Relationship - Alexandria Summit; American Association for Cancer Research; McCann Health